LNPEP, leucyl and cystinyl aminopeptidase, 4012

N. diseases: 174; N. variants: 13
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024668
Disease: Mammary Neoplasms, Experimental
Mammary Neoplasms, Experimental 		0.500 Biomarker phenotype RGD Insulin-regulated aminopeptidase/placental leucil Aminopeptidase (IRAP/P-lAP) and angiotensin IV-forming activities are modified in serum of rats with breast cancer induced by N-methyl-nitrosourea. 16619500 2006
CUI: C0024668
Disease: Mammary Neoplasms, Experimental
Mammary Neoplasms, Experimental 		0.500 Biomarker phenotype CTD_human Insulin-regulated aminopeptidase/placental leucil Aminopeptidase (IRAP/P-lAP) and angiotensin IV-forming activities are modified in serum of rats with breast cancer induced by N-methyl-nitrosourea. 16619500 2006
CUI: C0751295
Disease: Memory Loss
Memory Loss 		0.310 Biomarker phenotype BEFREE The development of inhibitors of insulin-regulated aminopeptidase (IRAP), a membrane-bound zinc metallopeptidase, is a promising approach for the discovery of drugs for the treatment of memory loss such as that associated with Alzheimer's disease. 21348480 2011
CUI: C0751295
Disease: Memory Loss
Memory Loss 		0.310 Biomarker phenotype CTD_human A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. 11730987 2001
CUI: C0025261
Disease: Memory Disorders
Memory Disorders 		0.300 Biomarker disease CTD_human A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. 11730987 2001
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.300 Biomarker phenotype CTD_human A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. 11730987 2001
CUI: C0751292
Disease: Age-Related Memory Disorders
Age-Related Memory Disorders 		0.300 Biomarker group CTD_human A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. 11730987 2001
CUI: C0751293
Disease: Memory Disorder, Semantic
Memory Disorder, Semantic 		0.300 Biomarker phenotype CTD_human A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. 11730987 2001
CUI: C0751294
Disease: Memory Disorder, Spatial
Memory Disorder, Spatial 		0.300 Biomarker phenotype CTD_human A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. 11730987 2001
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.220 Biomarker disease BEFREE The results revealed that the levels of phosphorylated tau protein at sites Ser199, Ser202 and Ser396 in hippocampus of T2D+CAP group were decreased significantly, but these phospho-sites in T2D+PF group didn't show such improvements compared with T2D group. 28225806 2017
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.220 Biomarker disease RGD In this study we measured the cell surface IRAP activity and 3-O-[methyl-14C]-D-Glucose uptake in adipocytes isolated from Otsuka Long Evans Tokushima Fatty rats (OLETF), developed as a model of type 2 diabetes mellitus, to evaluate whether the translocation of GLUT4/IRAP vesicles is affected. 16967782 2006
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.220 Biomarker disease BEFREE Impaired IRAP action may thus play a role in the development of complications in type 2 diabetes. 15187412 2004
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE We assessed the impact of the updated ASCO/CAP guidelines on 1044 FISH tested tumors by comparing categorization according to the 2007, 2013, and 2018 ISH classification criteria. 31375912 2020
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines. 31732618 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. 31076089 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE Misclassification of HER2 status was observed not only in breast cancers with ASCO-CAP equivocal status but also in breast cancers with an average of fewer than 4.0 HER2 copies per tumor cell when using alternative control probes. 30520947 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Misclassification of HER2 status was observed not only in breast cancers with ASCO-CAP equivocal status but also in breast cancers with an average of fewer than 4.0 HER2 copies per tumor cell when using alternative control probes. 30520947 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. 31076089 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE A total of 592 primary invasive BC cases from before and after the publication of the updated ASCO/CAP guideline were evaluated for HER2 amplification by silver ISH according to the 2013 and 2018 guidelines. 30953146 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines. 31732618 2019
CUI: C2985280
Disease: Blood Protein Measurement
Blood Protein Measurement 		0.100 GeneticVariation phenotype GWASCAT Genomic atlas of the human plasma proteome. 29875488 2018
CUI: C2985280
Disease: Blood Protein Measurement
Blood Protein Measurement 		0.100 GeneticVariation phenotype GWASCAT Co-regulatory networks of human serum proteins link genetics to disease. 30072576 2018
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. 28764718 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.100 Biomarker disease BEFREE The mean difference between HPS/CTM and CAP/CTM at baseline (n=153) was 0.32 log<sub>10</sub> IU/mL HCV RNA. 28259054 2017
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.100 Biomarker disease BEFREE However, cell cultures transfected with HCV and grown in medium containing TVR demonstrated that ART detected HCV RNA for a longer time than CAP/CTM. 28118381 2017